Ideas to Action:

Independent research for global prosperity

X

Global Health Policy Blog

Feed

GSK logoGSK has launched new trials of its candidate anti-malaria vaccine. Manhica Health Research Centre coordinator Betuel Sigauque told Reuters the new trials would involve 220 newborn babies in the rural Manhica district, 75 km (47 miles) from the capital Maputo.

Previous results indicated that after six months the vaccine had efficacy of 30 percent in reducing the first occurrence of the disease, 45 percent against primary infection by plasmodium falciparum -- the parasite responsible for the most acute form of malaria -- and 58 percent in severe malaria.

Sigauque said,

What we want to see now is the same vaccine administered in a younger group ... and see the efficacy when applied (under) a national vaccine programme.

Related Topics:

Disclaimer

CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions.